Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exelixis, Inc.
< Previous
1
2
3
4
Next >
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 23, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
May 28, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
May 20, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
May 07, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
April 30, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
April 16, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 27, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
February 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 01, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
January 25, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
January 23, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
January 18, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
January 07, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
January 02, 2024
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
December 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
December 04, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
November 21, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
November 10, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
October 22, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
October 18, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
September 12, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
August 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
August 23, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
August 21, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
July 23, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
July 18, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.